JP2017537968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537968A5 JP2017537968A5 JP2017532666A JP2017532666A JP2017537968A5 JP 2017537968 A5 JP2017537968 A5 JP 2017537968A5 JP 2017532666 A JP2017532666 A JP 2017532666A JP 2017532666 A JP2017532666 A JP 2017532666A JP 2017537968 A5 JP2017537968 A5 JP 2017537968A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkoxy
- hydrogen
- hydroxy
- protecting group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 217
- 229910052739 hydrogen Inorganic materials 0.000 claims description 216
- 239000001257 hydrogen Substances 0.000 claims description 216
- 150000002431 hydrogen Chemical class 0.000 claims description 194
- 125000003545 alkoxy group Chemical group 0.000 claims description 170
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 131
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 128
- 125000003282 alkyl amino group Chemical group 0.000 claims description 101
- 125000006239 protecting group Chemical group 0.000 claims description 100
- 125000000217 alkyl group Chemical group 0.000 claims description 93
- 125000004414 alkyl thio group Chemical group 0.000 claims description 93
- 125000006242 amine protecting group Chemical group 0.000 claims description 84
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 76
- -1 amino, hydroxy Chemical group 0.000 claims description 64
- 125000004429 atom Chemical group 0.000 claims description 52
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 32
- 125000004423 acyloxy group Chemical group 0.000 claims description 28
- 125000000732 arylene group Chemical group 0.000 claims description 28
- 125000002252 acyl group Chemical group 0.000 claims description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 22
- 125000004043 oxo group Chemical group O=* 0.000 claims description 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 20
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 20
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 19
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 14
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000006323 alkenyl amino group Chemical group 0.000 claims description 12
- 125000005108 alkenylthio group Chemical group 0.000 claims description 12
- 125000006319 alkynyl amino group Chemical group 0.000 claims description 12
- 125000005109 alkynylthio group Chemical group 0.000 claims description 12
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 12
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 150000001408 amides Chemical class 0.000 claims description 10
- 239000002841 Lewis acid Substances 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 8
- 150000007517 lewis acids Chemical class 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 4
- 125000005035 acylthio group Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 3
- 125000001118 alkylidene group Chemical group 0.000 claims description 3
- 229910052796 boron Inorganic materials 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000007800 oxidant agent Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229910052723 transition metal Inorganic materials 0.000 claims description 3
- 150000003624 transition metals Chemical class 0.000 claims description 3
- 150000002009 diols Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 description 9
- 0 CC(*)OC(C(C)(C(*)(*)C1(*)*)I)OC1=* Chemical compound CC(*)OC(C(C)(C(*)(*)C1(*)*)I)OC1=* 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000002231 Muscle Neoplasms Diseases 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000001348 alkyl chlorides Chemical group 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical group CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094662P | 2014-12-19 | 2014-12-19 | |
| US62/094,662 | 2014-12-19 | ||
| US201562186128P | 2015-06-29 | 2015-06-29 | |
| US62/186,128 | 2015-06-29 | ||
| PCT/US2015/066703 WO2016100833A2 (en) | 2014-12-19 | 2015-12-18 | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537968A JP2017537968A (ja) | 2017-12-21 |
| JP2017537968A5 true JP2017537968A5 (enExample) | 2019-01-31 |
Family
ID=56127867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532666A Withdrawn JP2017537968A (ja) | 2014-12-19 | 2015-12-18 | トリオキサカルシンｄｃ４５−ａ２の全合成及びトリオキサカルシン類似体の調製 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10899773B2 (enExample) |
| EP (1) | EP3233877A4 (enExample) |
| JP (1) | JP2017537968A (enExample) |
| KR (1) | KR20170122718A (enExample) |
| CN (1) | CN107250144A (enExample) |
| AU (1) | AU2015364347A1 (enExample) |
| BR (1) | BR112017013194A2 (enExample) |
| CA (1) | CA2970955A1 (enExample) |
| CL (1) | CL2017001599A1 (enExample) |
| CO (1) | CO2017007074A2 (enExample) |
| CR (1) | CR20170331A (enExample) |
| DO (1) | DOP2017000144A (enExample) |
| EA (1) | EA201791388A1 (enExample) |
| EC (1) | ECSP17046657A (enExample) |
| GT (1) | GT201700139A (enExample) |
| HK (1) | HK1243422A1 (enExample) |
| IL (1) | IL252947A0 (enExample) |
| MA (1) | MA41216A (enExample) |
| MX (1) | MX2017008162A (enExample) |
| PE (1) | PE20171787A1 (enExample) |
| PH (1) | PH12017501147A1 (enExample) |
| SG (1) | SG11201704935XA (enExample) |
| WO (1) | WO2016100833A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019036537A1 (en) * | 2017-08-17 | 2019-02-21 | William Marsh Rice University | ANALOGUES AND DIMER OF TRIOXACARCIN AS POWERFUL ANTICANCER AGENTS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5815995A (ja) | 1981-07-22 | 1983-01-29 | Kyowa Hakko Kogyo Co Ltd | Ｄｃ−４５−ａ↓１およびｄｃ−４５−ａ↓２ならびにそれらの製造法 |
| EP0157203A3 (en) * | 1984-04-04 | 1986-10-01 | American Cyanamid Company | Antitumor agents ll-d49194 alpha 1, ll-d49194 beta, ll-d49194 beta 2, ll-d49194 upsilon, ll-d49194 delta, ll-d49194 epsilon, ll-d49194 zeta, and ll-d49194 eta |
| JPS63135389A (ja) * | 1986-11-26 | 1988-06-07 | Kyowa Hakko Kogyo Co Ltd | Ｄｃ−４５類の誘導体 |
| US9102697B2 (en) | 2010-03-22 | 2015-08-11 | President And Fellows Of Harvard College | Trioxacarcins and uses thereof |
| US9775915B2 (en) * | 2012-11-26 | 2017-10-03 | President And Fellows Of Harvard College | Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof |
-
2015
- 2015-12-17 MA MA041216A patent/MA41216A/fr unknown
- 2015-12-18 CR CR20170331A patent/CR20170331A/es unknown
- 2015-12-18 AU AU2015364347A patent/AU2015364347A1/en not_active Abandoned
- 2015-12-18 MX MX2017008162A patent/MX2017008162A/es unknown
- 2015-12-18 CA CA2970955A patent/CA2970955A1/en not_active Abandoned
- 2015-12-18 US US15/537,319 patent/US10899773B2/en active Active
- 2015-12-18 CN CN201580076346.2A patent/CN107250144A/zh active Pending
- 2015-12-18 PE PE2017001101A patent/PE20171787A1/es unknown
- 2015-12-18 EA EA201791388A patent/EA201791388A1/ru unknown
- 2015-12-18 BR BR112017013194-3A patent/BR112017013194A2/pt not_active Application Discontinuation
- 2015-12-18 HK HK18102899.8A patent/HK1243422A1/zh unknown
- 2015-12-18 EP EP15871176.2A patent/EP3233877A4/en not_active Withdrawn
- 2015-12-18 WO PCT/US2015/066703 patent/WO2016100833A2/en not_active Ceased
- 2015-12-18 JP JP2017532666A patent/JP2017537968A/ja not_active Withdrawn
- 2015-12-18 KR KR1020177020092A patent/KR20170122718A/ko not_active Withdrawn
- 2015-12-18 SG SG11201704935XA patent/SG11201704935XA/en unknown
-
2017
- 2017-06-15 IL IL252947A patent/IL252947A0/en unknown
- 2017-06-19 DO DO2017000144A patent/DOP2017000144A/es unknown
- 2017-06-19 GT GT201700139A patent/GT201700139A/es unknown
- 2017-06-19 PH PH12017501147A patent/PH12017501147A1/en unknown
- 2017-06-19 CL CL2017001599A patent/CL2017001599A1/es unknown
- 2017-07-14 CO CONC2017/0007074A patent/CO2017007074A2/es unknown
- 2017-07-19 EC ECIEPI201746657A patent/ECSP17046657A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6177975B2 (ja) | ポリエチレングリコールベースのアドレノメデュリンのプロドラッグおよびその使用 | |
| JP2019519503A5 (enExample) | ||
| JP4391087B2 (ja) | 癌の処置のための薬学的組み合わせ | |
| CA2421562A1 (en) | A method of producing analgesia using sodium channel blocking compounds such as tetrodotoxin, saxitoxin and derivatives thereof | |
| JP2004508404A5 (enExample) | ||
| US9469648B2 (en) | Reversal of drug-induced neuromuscular block using novel molecular containers | |
| JP2018509404A5 (enExample) | ||
| KR20110013411A (ko) | (ｆ-19)-표지된 ｌ-글루탐산 및 ｌ-글루타민 유도체 (ⅲ), 그의 용도 및 그의 수득 방법 | |
| WO2015129809A1 (ja) | 虚血性眼疾患の処置用の医薬組成物 | |
| AU2018370019A1 (en) | Stable compositions of pegylated carfilzomib compounds | |
| JP2017537968A5 (enExample) | ||
| US8835466B2 (en) | Synthesis and uses of pyroglutamic acid derivatives | |
| CN105263501A (zh) | 具有抗转移活性的糖-类似物含磷杂环 | |
| JP6545254B2 (ja) | リン含有フェナントロリン誘導体及びその調製方法と応用 | |
| US20080293648A1 (en) | Compositions and Methods for Cancer Treatment | |
| US10111955B2 (en) | PEG derivative | |
| JP2011514356A5 (enExample) | ||
| JP2017513934A5 (enExample) | ||
| TW200829261A (en) | Method for controlling angiogenesis in animals | |
| JPWO2020206289A5 (enExample) | ||
| JP2010500971A5 (enExample) | ||
| ES2884945T3 (es) | Derivados de piperazina para el tratamiento de la hipertensión y/o la fibrosis | |
| TW202108136A (zh) | 用於治療睡眠呼吸中止之α2-腎上腺素受體亞型C(α-2C)拮抗劑 | |
| TWI757573B (zh) | 化合物在製備治療出血性腦中風的藥物中的應用 | |
| JP2018527372A5 (enExample) |